Core Viewpoint - Yuan Da Pharmaceutical (00512) has seen a stock price increase of over 3% during trading, currently up 2.59% at HKD 8.32, with a trading volume of HKD 33.37 million. The company recently announced that its innovative traditional Chinese medicine GPN01360 for treating depression has reached clinical endpoints in a Phase II clinical study in China [1]. Group 1: Clinical Research and Product Development - GPN01360 is a Class 1 innovative traditional Chinese medicine designed to treat depression (specifically liver qi stagnation and spleen deficiency syndrome), based on the ancient formula "Xiao Yao San" [1]. - The formulation consists of 12 traditional Chinese medicinal ingredients, including Chai Hu, Yu Jin, and Fo Shou, which are believed to have effects such as soothing the liver, strengthening the spleen, and calming the mind [1]. - Positive clinical research data is expected to lay a foundation for the further development of GPN01360, potentially addressing the issue of poor patient compliance associated with side effects of existing Western medications [1]. Group 2: Market Implications and Evidence - The innovative approach of GPN01360 may enhance the sustainability and effectiveness of long-term treatment for depression, contributing to improved clinical cure rates [1]. - GPN01360 is anticipated to provide robust evidence for the efficacy of traditional Chinese medicine in treating mental health disorders, validating the unique advantages and scientific value of traditional Chinese formulations [1].
远大医药盘中涨超3% 中药创新药GPN01360国内II期临床达到终点